Senti Biosciences

Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026 bit.ly/3QgGnqb $SNTI #CellTherapy #Oncology #AML

Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies bit.ly/4cgkRue $SNTI #CellTherapy #Oncology #AML

Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update bit.ly/3PBFecv $SNTI #CellTherapy #Oncology #AML

Founded to develop a new generation of smarter medicines, Senti Biosciences is advancing innovative approaches to outsmart complex diseases and redefine what’s possible in medicine. $SNTI #Oncology #AML

Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference bit.ly/4t6OzHS $SNTI #CellTherapy #Oncology #AML

Want to hear about our latest progress? Stay in the loop by signing up for our email alerts. bit.ly/3ZVnb39 $SNTI #Oncology #AML

Senti Biosciences is heading to the Leerink Global Healthcare Conference, March 8-11 in Miami Beach, FL! Join us for our presentation on March 9th from 2:20–2:50 PM as we share updates on our cell engineering platform and pipeline. Don't Miss It: bit.ly/3MIYyDL $SNTI

Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026, at 2:20 PM ET bit.ly/4ubbJ1a $SNTI #CellTherapy #Oncology #AML

Senti Bio is a clinical-stage company advancing a new generation of cell and gene therapies for patients living with incurable diseases. $SNTI #Oncology #AML

Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference on Monday, March 2nd at 3:10 PM ET bit.ly/4aPOAs2 $SNTI #CellTherapy #Oncology #AML

Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development bit.ly/4rZXiLe #CellTherapy #Oncology #AML

Stay up to date on our latest news, clinical progress and company updates. Sign up for email alerts: bit.ly/3ZVnb39 $SNTI #Oncology #AML

#DidYouKnow Each year, more than 20,000 people in the U.S. are diagnosed with #AML, and many face relapse or poor outcomes within the first year. This highlights a significant unmet need for new, innovative treatment approaches. $SNTI #Oncology

Thank you, David Wild of InVivo, for taking the time to explore and cover our success in addressing a central challenge in oncology, and for highlighting our clinical and regulatory milestones in advancing a first-in-class AML therapy. Find out more here: bit.ly/4kyiJAE

Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) bit.ly/4kABuDI $SNTI #CellTherapy #Oncology #AML

February is National Cancer Prevention Month. Senti Bio remains focused on advancing next-generation science to help change the future of cancer care. $SNTI #Oncology #AML

Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026 on Tuesday, February 10, 2026, from 10:30 AM to 10:40 AM local time, in Track 1 at the Regent Ballroom (Level 3). bit.ly/4tkRRZ4 #CellTherapy #Oncology #AML

Nearly 10% of new cancer cases in the U.S. are blood cancers like leukemia, lymphoma, and myeloma. Behind every statistic is a person, a family, a story. At $SNTI, we’re working to bring them new hope through smarter, more precise cell therapies. #AML #Leukemia #Oncology

An article titled “Senti Bio Wins FDA RMAT Designation for SENTI-202 on 50% Response Rate in Leukemia Trial” was recently published by GeneOnline, highlighting the FDA’s RMAT designation for SENTI-202 and encouraging early clinical results in AML. 🔗: bit.ly/4aLcQ03

$SNTI has been selected as one of 10 overseas companies named to the Japan Entry Acceleration Program in the field of regenerative medicine. This selection reflects our innovation and expanding global footprint in cell and gene therapy. Learn more: bit.ly/45XgRLD